Tempest to Participate in William Blair 2021 Biotech Focus Conference
Tempest Therapeutics (Nasdaq: TPST) announced that Dr. Sam Whiting, the chief medical officer, will join a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on July 14, 2021, at 2:10 p.m. ET. Tempest is advancing clinical programs TPST-1495 and TPST-1120, which target EP2/EP4 and PPARα, respectively, through Phase 1 studies. The company aims to develop innovative therapies combining targeted and immune-mediated mechanisms to treat various tumors. More details are available on their investor website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiting, M.D., Ph.D., chief medical officer, will participate in a webcast panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on Wednesday, July 14, 2021 at 2:10 p.m. ET.
To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Tempest Therapeutics participating in the William Blair 2021 Biotech Focus Conference?
Who from Tempest Therapeutics is speaking at the conference?
What is the focus of the panel discussion Dr. Whiting will participate in?
What clinical programs is Tempest Therapeutics currently advancing?
What mechanisms do TPST-1495 and TPST-1120 target?
